Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 34310172

Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
J Clin Oncol
Publication date
2021 Nov 1
First author
Byrd JC

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    J Clin Oncol. 2021 Nov 1;39(31):3419-3422. doi: 10.1200/JCO.21.01414.
    note
    Source null
    related pmid
    34310198
    relationship
    Comment in

Authors and identifiers

  1. name
    Byrd JC
    type
    Author
  2. name
    Hillmen P
    type
    Author
  3. name
    Ghia P
    type
    Author
  4. name
    Kater AP
    type
    Author
  5. name
    Chanan-Khan A
    type
    Author
  6. name
    Furman RR
    type
    Author
  7. name
    O'Brien S
    type
    Author
  8. name
    Yenerel MN
    type
    Author
  9. name
    Illés A
    type
    Author
  10. name
    Kay N
    type
    Author
  11. name
    Garcia-Marco JA
    type
    Author
  12. name
    Mato A
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Byrd JC
    type
    Author
  2. name
    Hillmen P
    type
    Author
  3. name
    Ghia P
    type
    Author
  4. name
    Kater AP
    type
    Author
  5. name
    Chanan-Khan A
    type
    Author
  6. name
    Furman RR
    type
    Author
  7. name
    O'Brien S
    type
    Author
  8. name
    Yenerel MN
    type
    Author
  9. name
    Illés A
    type
    Author
  10. name
    Kay N
    type
    Author
  11. name
    Garcia-Marco JA
    type
    Author
  12. name
    Mato A
    type
    Author
bibliography ids
  1. nci-bib-b36b6c8796800fe87b1cb2c7
book metadata
content sha256
36755e2dac1b2d9cb535c235885dfe061e46004d6439607c95e8ef0602ab1249
document type
citation
dois
  1. 10.1200/JCO.21.01210
electronic publication date
display
2021 Jul 26
precision
day
year
2021
evidence scope
bibliographic_metadata_only
id
pubmed:34310172
immutable id
pubmed:34310172@36755e2dac1b2d9cb535c235885dfe061e46004d6439607c95e8ef0602ab1249
journal
abbreviation
J Clin Oncol
issn electronic
1527-7755
issn print
0732-183X
issue
31
name
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
nlm unique id
8309333
pages
3441-3452
volume
39
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    J Clin Oncol. 2021 Nov 1;39(31):3419-3422. doi: 10.1200/JCO.21.01414.
    note
    Source null
    related pmid
    34310198
    relationship
    Comment in
outcomes validated
false
pmid
34310172
provenance
batch id
192b6392c165c6b06274
provider
NCBI PubMed ESummary
record sha256
3f2e571212a096de9b7094a27d0bff939b5487aa00b7e34082ce6426bedb8742
response sha256
7d81e9fb11ee99e6ad4116aecd61ba71cd6bf76f2a8f8f6d15c5c85e9c6c56b4
retrieved at
2026-09-09T23:48:02.713075+00:00
publication date
display
2021 Nov 1
precision
day
year
2021
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Multicenter Study
  5. Randomized Controlled Trial
  6. Research Support, N.I.H., Extramural
  7. Research Support, Non-U.S. Gov't
  8. Equivalence Trial
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/34310172/
title
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial.

Preserved source evidence · Not medical advice